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Abstract
Repeated intermittent treatment with amphetamine (AMPH)
induces both neurite outgrowth and enhanced AMPH-stimu-
lated dopamine (DA) release in PC12 cells. We investigated
the role of protein kinases in the induction of these AMPH-
mediated events by using inhibitors of protein kinase C (PKC),
mitogen activated protein kinase (MAP kinase) or protein
kinase A (PKA). PKC inhibitors chelerythrine (100 nM and
300 nM), Ro31-8220 (300 nM) and the MAP kinase kinase
inhibitor, PD98059 (30 lM) inhibited the ability of AMPH to
elicit both neurite outgrowth and the enhanced AMPH-stimu-
lated DA release. The direct-acting PKC activator,
12-O-tetradecanoyl phorbol 13-acetate (TPA, 250 nM) mim-
icked the ability of AMPH to elicit neurite outgrowth and
enhanced DA release. On the contrary, a selective PKA
inhibitor, 100 lM Rp-8-Br-cAMPS, blocked only the develop-
ment of AMPH-stimulated DA release but not the neurite
outgrowth. Treatment of the cells with acute AMPH elicited an
increase in the activity of PKC and MAP kinase but not PKA.
These results demonstrated that AMPH-induced increases in
MAP kinase and PKC are important for induction of both the
enhancement in transporter-mediated DA release and neurite
outgrowth but PKA was only required for the enhancement in
AMPH-stimulated DA release. Therefore the mechanisms by
which AMPH induces neurite outgrowth and the enhancement
in AMPH-stimulated DA release can be differentiated.
Keywords: cultured cells, extracellular signal-regulated kin-
ase, neurite outgrowth, protein kinases, repeated amphet-
amine, transporter-mediated dopamine release.
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Amphetamine (AMPH), a synthetic psychomotor stimulant,
acts as an indirect agonist of catecholaminergic systems.
AMPHexerts its physiological effects by enhancing the release
of dopamine (DA) and norepinephrine from nerve terminals
into the synapse through a reversal of their respective
plasmalemmal transporters, the dopamine transporter (DAT)
and norepinephrine transporter (NET) (Seiden et al. 1993).
Repeated, intermittent treatment of rats with AMPH leads to
both a behavioral sensitization and neuroadaptations that
include an enhanced release of DA from striatum and nucleus
accumbens in response toAMPH (Robinson and Becker 1986;
Robinson 1991; Kantor and Gnegy 1998a; Wolf 1998). There
is morphological evidence that AMPH can remodel synapses
in rat brain by increasing the density of synapses and number of
dendritic spines in rat nucleus accumbens and prefrontal cortex
(Robinson and Kolb 1997, 1999).
We found that neurite outgrowth and enhanced transpor-
ter-mediated DA release occur in rat pheochromocytoma
PC12 cells in response to repeated, intermittent AMPH,
Received July 18, 2003; revised manuscript received September 8, 2003;
accepted September 9, 2003.
Address correspondence and reprint requests to Margaret E. Gnegy,
Department of Pharmacology, 2220 MSRB III, University of Michigan
School of Medicine, 1150 W. Medical Center, Ann Arbor, MI 48109-
0632, USA. E-mail: pgnegy@umich.edu
Abbreviations used: AMPH, amphetamine; DA, dopamine; DAT,
dopamine transporter; MAP kinase, mitogen activated protein kinase;
MEK, MAP kinase kinase; NET, norepinephrine transporter; NGF, nerve
growth factor; PKA, protein kinase A; PKC, protein kinase C; TBST,
Tris-buffered saline (containing 0.1% Tween 20); TPA, 12-O-tetradeca-
noyl phorbol 13-acetate; VTA, ventral tegmental area.
Journal of Neurochemistry, 2003, 87, 1546–1557 doi:10.1046/j.1471-4159.2003.02127.x
1546  2003 International Society for Neurochemistry, J. Neurochem. (2003) 87, 1546–1557
reminiscent of those occurring in brain. The PC12 cell can be
a useful single-cell model in which to investigate molecular
mechanisms of acute and repeated AMPH, although the
PC12 cells are not neurons. These cells contain endogenous
norepinephrine and DAwhich can be released in response to
AMPH through plasmalemmal NET (Greene and Tischler
1976; Bonisch 1984; Kantor et al. 2002). In addition, PC12
cells characteristically differentiate in response to trophic
factors such as nerve growth factor (NGF) (Koike 1983;
Nakafuku and Kaziro 1993). Repeated, intermittent treatment
with AMPH induced neurite outgrowth in PC12 cells in a
process that required the plasmalemmal transporter (Park
et al. 2002). The identical AMPH treatment concurrently
induced an enhancement in AMPH-stimulated DA release in
PC12 cells that had characteristics analogous to those found
in striatum and nucleus accumbens (Kantor et al. 2002). The
fact that repeated, intermittent AMPH can elicit these
neuroadaptations in the PC12 cells demonstrates that these
responses can be achieved within the catecholaminergic cell
and does not require an intact neuroanatomy. It also suggests
that PC12 cells are an appropriate model in which to
investigate the mechanisms of induction of the neuroadap-
tations by repeated AMPH.
Protein kinase-dependent signal transduction is a factor
both in the action of stimulants such as AMPH and in neurite
outgrowth. Protein kinase C (PKC), a Ca2+/lipid-dependent
serine and threonine kinase, plays a pivotal role in the
regulation of many cellular processes, including release of
catecholamines, catecholamine plasmalemmal transporter
trafficking (Blakely et al. 1998; Daniels and Amara 1999)
and cellular neurite outgrowth (Nishizuka 1988; Ben-Shlomo
et al. 1991; Hug and Sarre 1993). PKC activation is involved
in AMPH-induced outward transport of DA through both
DAT, as demonstrated in brain, and through NET, as shown
in PC12 cells (Ben-Shlomo et al. 1991; Giambalvo 1992a,b;
Kantor and Gnegy 1998b; Cowell et al. 2000; Kantor et al.
2001, 2002). Similarly, PKC plays a part in AMPH-mediated
locomotion (Browman et al. 1998).
Mitogen activated protein kinase (MAP kinase) is also
involved in the behavioral sensitization in animals to psycho-
stimulants and dopamine transporter function (Rothman et al.
2002; Licata and Pierce 2003). Intra-ventral tegmental area
(VTA) injection of MAP kinase kinase (MEK) inhibitors
blocks the initiation of behavioral sensitization to cocaine
(Pierce et al. 1999). Similarly, repeated treatment with cocaine
increases the phosphorylation of MAP kinase in the VTA
(Berhow et al. 1996). Since protein kinase A (PKA) also
contributes to psychostimulant sensitization (Self et al. 1998),
this kinase could be important in the induction of the
neuroadaptations elicited in response to repeated, intermittent
AMPH as well. cAMP signal transduction is important for the
induction of the persistent behavioral sensitization following
repeated administration of AMPH in the DA cell bodies in the
VTA (Tolliver et al. 1999).
All three of these protein kinases, PKA (Yao et al. 1998;
Hansen et al. 2000; Jessen et al. 2001), PKC (Hall et al.
1988; Borgatti et al. 1996) and MAP kinase (Koike 1983;
Nakafuku and Kaziro 1993) play a role in neurite outgrowth
in PC12 cells.
Therefore we investigated whether PKC, MAP kinase or
PKA is involved in the induction of AMPH-elicited neurite
outgrowth and enhanced DA release in PC12 cells after
repeated, intermittent treatment with AMPH. In addition, we
also determined whether the AMPH-induced neurite out-
growth and enhanced AMPH-stimulated DA release are
induced through activation of identical signaling pathways.
Materials and methods
Materials
D-Amphetamine sulfate, 12-O-tetradecanoyl phorbol 13-acetate
(TPA) and forskolin were purchased from Sigma (St. Louis, MO,
USA). Chelerythrine, Ro31-8220, Rp-8-Br-cAMPS, PD98059 and
H-89 were purchased from Calbiochem (La Jolla, CA, USA).
Cell culture
PC12 cells were maintained in a 75-cm2 tissue culture flask in
growth medium composed of Dulbecco’s modified Eagle’s medium
from BioWhittaker (Walkersville, MD, USA) supplemented with
10% (v/v) heat-inactivated fetal bovine serum, 5% heat-inactivated
horse serum, 2 mM L-glutamine, 100 lg/mL of streptomycin and
100 U/mL of penicillin (Gibco, Rockville, MD, USA) and were
incubated at 10% CO2. To induce neurite outgrowth, 5 · 104 cells/
mL were plated in a 75-cm2 tissue culture flask at 10% CO2 in the
same growth medium. PC12 cells were treated with 1 lM AMPH
(Sigma) for 5 min a day for 5 days. After a 10-day drug-free period
(withdrawal), cells were analyzed for neurite outgrowth and AMPH-
stimulated DA release. To block the activity of protein kinases, the
inhibitors were added to the media for either 30 min (chelerythrine,
Ro31-8220, PD98059 or H-89) or 1 h (Rp-8-Br-cAMPS) before the
AMPH. This treatment paradigm is outlined in the schema in
Fig. 1(a). To activate PKC or PKA, PC12 cells were treated with
250 nM TPA or 10 lM forskolin for 5 min a day for 5 days in the
same manner as with AMPH.
Quantification of neurite outgrowth
To analyze neurite outgrowth, pictures of the PC 12 cells were taken
with a digital camera (SPOT RT, Diagnostic Instrument Inc., Sterling
Heights, MI, USA) at 200· phase contrast using a Leica DMI RB
inverted microscope. For each treatment, randomly chosen individual
areas (containing ‡ 80 cells) were scored in the digital pictures.
A neurite was counted when a cellular process was longer than
the diameter of the cell body. The percentage of neurite outgrowth
was calculated as the number of cells with neurites divided by total
cell numbers (Park et al. 2002). Each experiment was conducted in
triplicate.
Superfusion assay
Cells were harvested by washing the flasks with Kreb’s Ringer
buffer containing 125 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2,
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1.2 mM CaCl2, 1.2 mM KH2PO4, 10 mM glucose, 24.9 mM NaHCO3
and 0.25 mM ascorbic acid and oxygenated by 95% O2 and 5% CO2
for 1 h. DA release was measured in the superfused cells by HPLC
with electrochemical detection as described previously (Kantor et al.
2002).
PKC assay
Cells were washed in serum-free media and resuspended in the same
media and incubated at 37C with or without 3 lM AMPH for
5 min. Cold phosphate-buffered saline was added to the samples
and the cells were centrifuged at 800 · g for 3 min. Cells were
washed twice with cold phosphate-buffered saline and lysed in an
extraction buffer containing 25 mM Tris-HCl (pH 7.4), 0.5 mM
EGTA, 0.5 mM EDTA, 10 mM dithiothreitol and protease inhibitor
cocktail, by sonication for 60 s in an ice bath. Lysates were
centrifuged at 800 · g to remove cell debris and then centrifuged at
100 000 · g for 1 h. The supernatant was designated as the
cytosolic fraction. The pellet was then extracted with extraction
buffer containing 0.25% Triton X-100 at 4C for 1 h and centrifuged
at 100 000 · g for 30 min. The solubilized material was designated
as the membrane fraction. Both the cytosolic and membrane
fractions were loaded on 0.5 mL DE-52 columns pre-equilibrated
with their respective extraction buffers. Columns were washed with
five column volumes of buffer and then eluted with buffer
containing 0.2 M NaCl. Eluates were assayed for PKC activity.
PKC activity was assayed using SignaTECT PKC assay system
fromPromega (Madison,WI, USA). Briefly, extracts were assayed for
PKC activity using a biotinylated substrate peptide, corresponding to
the PKC phosphorylation site in neurogranin. The assay (25 lL
volume) contained 10 mM MgCl2, 0.4 mM CaCl2, 100 lM substrate,
and 100 lM ATP (containing 0.05 lCi of [c-32P]ATP/assay) in the
presence and absence of 0.32 mg/mL phosphatidyl serine and
0.032 mg/mL diacylglycerol. Reactions were started by adding the
sample and incubating at 30C for 5 min. Reactions were terminated
by adding 7.5 M guanidine hydrochloride and 10 lL of the reaction
was spotted on a special biotin capturemembrane. Themembrane was
washed sequentially four times in 2 M NaCl followed by four times in
2 M NaCl in 1% phosphoric acid and dried and counted by liquid
scintillation. Enzyme activity is expressed as pmols of 32P transferred
to the substrate per min per mg protein.
(a)
Fig. 1 (a) Schema representing repeated,
intermittent treatment of PC12 cells. PC12
cells were treated with vehicle (control) or
1 lM AMPH following a 30 or 60 min pre-
treatment with protein kinase inhibitors or
vehicle. Following a 10-day drug-free per-
iod, neurite outgrowth and DA release in
response to a challenge of 1 lM AMPH was
measured. In some experiments, 250 nM
TPA or 10 lM forskolin is substituted for the
1 lM AMPH in the repeated treatments.
(b–j) Involvement of protein kinases in
AMPH-induced neurite outgrowth in PC12
cells. PC12 cells were treated with repeated,
intermittent vehicle (b), AMPH (c–e, g–i) or
protein kinase activators (f, j) for 5 min per
day for 5 days as described in Materials and
Methods and Fig. 1(a). Protein kinase
inhibitors (d, e, g–i) were given before each
AMPH treatment as shown in Fig. 1(a). The
treatments were: (b) vehicle, (c) 1 lM AMPH,
(d) 100 nM chelerythrine + AMPH, (e)
300 nM Ro31-8220 + AMPH, (f) 250 nM
TPA, (g) PD98059 + AMPH, (h) 500 nM
H89 + AMPH, (i) 100 lM Rp-8-Br-cAMPS +
AMPH and (j) forskolin. Ten days following
the last AMPH treatment, pictures of PC12
cells were taken by digital camera SPOT RT
at 200·phase contrast. Scale bar represents
100 lm.
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PKA assay
PC12 cells were washed with serum-free media and resuspended
in the same media. Cells were then incubated at 37C and treated
without or with 3 or 10 lM AMPH for 5 min. At the end of the
incubation, 0.5 mL of cold phosphate-buffered saline was added
to the cells and they were centrifuged at 800 g for 3 min. Cells
were washed twice with cold phosphate-buffered saline and lysed
in 0.2 mL of lysis buffer (10 mM potassium phosphate, 0.25 M
sucrose, 1 mM EDTA, 1 mM dithiothreitol containing protease
inhibitor cocktail) by sonication for 5 min in an ice bath. The
lysate was centrifuged at 10 000 · g for 15 min in a microcen-
trifuge and the supernatant was used for the assay of PKA
activity.
PKA activity was assayed in a volume of 50 lL in a buffer
containing 10 mM HEPES, pH 7.4, 10 mM dithiothreitol, 5 mM
sodium fluoride, 10 mM magnesium chloride, 0.5 mM IBMX and
0.2 mM ATP using 30 lM kemptide as substrate in the presence and
absence of 30 lM cAMP. The reaction was allowed to proceed for
5 min at 30C and stopped by spotting 25 lL of the reaction mix on
a P81 strip. The strips were washed four times in 75 mM phosphoric
acid, dried and counted using Scintverse BD in a Beckman LS5800
liquid scintillation counter. The cAMP-dependent activity of PKA is
defined as pmols of radioactive phosphate transferred to the
substrate per min per mg protein.
Protein extraction and immunoblotting for GAP-43 and MAP
kinases
Cells were treated at 37C without or with 3 lM AMPH for 5 min.
For GAP-43 phosphorylation, PC12 cells were extracted with
150 lL of 2.5% perchloric acid, 150 mM NaCl and 1% Triton
X-100. Extracts were sonicated for 15 min in a water bath and
centrifuged at 15 000 · g for 10 min. Percholoric acid-soluble
protein was neutralized with 2 N NaOH. For MAP kinase, PC12
cells were lysed in 10 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100, 5 mM EGTA and 5 mM EDTA with the protease inhibitor
cocktail tablets, Complete Mini (1 tablet/10 mL of buffer) (Roche,
Mannheim, Germany) and 1 mM sodium orthovanadate. Nuclei and
undisrupted cells were removed by spinning at 1000 · g. Protein
concentration was determined by a modified Lowry method (D-C
protein assay kit, Bio-Rad, Hercules, CA, USA).
Samples (20 lg protein each) were resolved by electrophoresis
on 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
gels and transferred to a polyvinylidene difluoride membrane.
Membranes were blocked with 5% milk in Tris-buffered saline
containing 0.1% Tween 20 (TBST) and incubated in 2.5% milk in
TBST with rabbit anti-phosphoserine41-GAP-43 (Chemichon,
Temecula, CA, USA) (1 : 1000 dilution, overnight), rabbit anti-
GAP-43 (Chemichon) (1 : 1000, 1 h), mouse anti-phospho-p44/42
MAPK (Cell signaling, San Francisco, CA, USA) (1 : 1000
dilution, overnight) or rabbit anti-p44/42 MAPK (Cell signa-
ling) (1 : 1000 dilution, 1 h). After three washes with TBST,
membranes were incubated with a secondary antibody conjugated
with horseradish peroxidase. (1 : 10 000) (Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA). The immunoblots were developed
using enhanced chemiluminescence (Amersham Bioscience, Pisca-
taway, NJ, USA). To quantify the GAP-43 blots, the films were
scanned and the density of each band was measured by using the
NIH images program (Scion corporation, Frederick, MD, USA).
Data analysis
Statistical significance between two groups was determined using a
two-tailed Student’s t-test. Analysis among three or more groups
was conducted using one-way analysis of variants (ANOVA) with
post-test Tukey–Kramer multiple comparison analysis.
Results
AMPH-induced neurite outgrowth and enhanced AMPH-
stimulated DA release depended on PKC in PC12 cells
To investigate the role of PKC in AMPH-induced neurite
outgrowth, PC12 cells were pre-treated with a PKC inhibitor,
either chelerythrine or Ro31-8220, for 30 min before each
daily AMPH treatment. These drugs are structurally dissi-
milar and have been shown to block AMPH-stimulated DA
release in rat striatum and PC12 cells (Kantor and Gnegy
1998b; Kantor et al. 2001). After 10 drug-free days, neurite
outgrowth was measured using digital pictures. As we
showed previously (Park et al. 2002), AMPH induced
neurite outgrowth in PC12 cells (Figs 1b and c). Both
chelerythrine (Fig. 1d) and Ro31-8220 (Fig. 1e) significantly
blocked the ability of AMPH to induce neurite outgrowth in
PC12 cells but did not alter basal neurite outgrowth (Fig. 2a).
As shown in Fig. 2(a), both drugs at 300 nM blocked the
induction of the neurite outgrowth in response to AMPH. To
further demonstrate participation of PKC in the neurite
outgrowth, PC12 cells were treated with 250 nM of the PKC
activator TPA in a manner identical to that of AMPH. This
concentration of TPA was previously shown to induce DA
release non-additively with AMPH through NET (Cowell
et al. 2000). Ten days following the repeated TPA treatment,
neurite outgrowth was measured. The repeated, intermittent
TPA treatment induced a significant increase in neurite
outgrowth in PC12 cells as compared to vehicle (Fig. 1f).
There was no significant difference in the percentage of cells
exhibiting neurites following the AMPH and TPA treatments
(Fig. 2b).
Repeated, intermittent treatment of the PC12 cells with
AMPH results in an enhancement of DA release to a
subsequent challenge of AMPH in the perfusion (Kantor
et al. 2002) just as occurs in the rat striatum following
repeated treatment of the rat with AMPH (Kantor et al.
1999). To investigate whether the induction of the enhanced
DA release is also dependent on PKC activity, the PC12 cells
were pre-treated with chelerythrine or Ro31-8220 before the
daily AMPH treatment as described above. After the 10
drug-free days, AMPH-mediated DA release was measured.
Pre-treatment of the PC12 cells with the PKC inhibitors
chelerythrine and Ro31-8220 before each AMPH treatment
effectively inhibited the induction of enhanced DA release to
a challenge dose of AMPH (Figs 3a and b). The drugs had no
effect on basal DA release. To confirm that a repeated
activation of PKC by AMPH results in the enhancement in
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transporter-mediated DA release, the PC12 cells were treated
with 250 nM TPA instead of 1 lM AMPH for each of 5 days
and given 10 drug-free days. As shown in Fig. 3(c), the
repeated TPA treatment mimicked the ability of repeated
AMPH to induce the enhancement in AMPH-stimulated DA
release.
The MEK inhibitor, PD98059 blocked AMPH-induced
neurite outgrowth and enhanced AMPH-stimulated DA
release in PC12 cells
To investigate whether MAP kinase activity is required for
the induction of AMPH-induced neurite outgrowth, PC12
cells were treated with 1 lM AMPH for 5 min a day for
5 days in the absence or presence of 30 lM of the MEK
inhibitor, PD98059. After 10 drug-free days, neurite out-
growth was measured. PD98059 pre-treatment inhibited the
repeated AMPH-induced neurite outgrowth in the PC12 cells
by 70% (Figs 1g and 4a). We investigated whether MAP
kinase activation is similarly necessary for the induction of
enhanced AMPH-stimulated DA release after repeated,
intermittent AMPH. PC12 cells were treated with the same
protocol as for neurite outgrowth. After 10 drug-free days,
PC12 cells were challenged with AMPH and DA release was
measured by HPLC. Pre-treatment with the MEK inhibitor,
PD98059, inhibited the induction of AMPH-stimulated
enhanced DA release demonstrating that both neuroadapta-
tions require the activation of MAP kinase (Fig. 4b). It has
been reported that PD98059 can block DA uptake (Rothman
et al. 2002). However, 30 lM PD98059 did not inhibit DA
release in response to acute AMPH (in the perfusion) in
untreated cells.
The PKA inhibitor Rp-8-Br-cAMPS did not block
AMPH-induced neurite outgrowth but inhibited
enhanced AMPH-stimulated DA release in PC12 cells
To determine whether PKA contributes to AMPH-induced
neurite outgrowth, the PKA inhibitors H-89 and Rp-8-Br-
cAMPS were used. Pre-treatment with 500 nM H-89, given
30 min before each repeated AMPH treatment, blocked the
induction of neurite outgrowth in response to repeated,
intermittent AMPH (Figs 1h and 5a). On the contrary, Rp-
8-Br-cAMPS, a potent cell-permeable metabolically stable
cAMP antagonist that is highly specific for inhibition of
PKA, did not block AMPH-induced neurite outgrowth when
given at either 30 lM or 100 lM 1 h before each AMPH
treatment (Figs 1i and 5a). Rp-8-Br-cAMPS alone did not
affect basal neurite outgrowth. To further understand the role
of PKA in the neurite outgrowth, PC12 cells were also
treated with 10 lM forskolin, an adenylyl cyclase activator,
in a manner identical to that of AMPH. Ten days following
the repeated forskolin treatment, neurite outgrowth was
measured. In contrast to AMPH, the repeated, intermittent
forskolin treatment did not induce neurite outgrowth in PC12
cells (Figs 1j and 5b).
To further compare the mechanism of induction of neurite
outgrowth and enhanced DA release, the role of PKA in
enhanced AMPH-stimulated DA release was investigated.
Either Rp-8-Br-cAMPS or H-89 was added to the media
before each of the five AMPH treatments. After 10 drug-free
days, DA release in response to a challenge of 1 lM AMPH
was measured in perfused cells. In contrast to the develop-
ment of neurite outgrowth, both Rp-8-Br-cAMPS and H-89
pre-treatment significantly blocked the ability of repeated
AMPH to induce an enhancement in AMPH-stimulated DA
release as compared to vehicle (Fig. 5c). The drugs had no
effect on basal DA release. To determine whether direct
activation of PKA can mimic AMPH in the induction of
enhanced DA release, PC12 cells were treated with 10 lM
forskolin for 5 min a day for 5 days. After 10 drug-free days,
AMPH-stimulated DA release was measured. In contrast to
direct PKC activation, repeated forskolin did not mimic the
ability of repeated AMPH to elicit enhanced
Fig. 2 Effect of PKC inhibition or activation on AMPH-induced neurite
outgrowth. (a) PC12 cells were treated with 1 lM AMPH (AMPH,
x-axis) or vehicle (control, x-axis) for 5 min per day for 5 days. Before
each vehicle or AMPH treatment, PC12 cells were pre-treated with
vehicle, 100 nM or 300 nM chelerythrine or 300 nM Ro 31–8220 for
30 min (pre-treatments are given in the legend in the Figure). After 10
drug-free days, neurite outgrowth was measured as described in
Material and Methods. Values represent means ± SEM. n ‡ 3. ANOVA,
p < 0.0001. In post hoc Tukey–Kramer analysis **p < 0.001 vs. con-
trol. *p < 0.05 and #p < 0.001 vs. vehicle-AMPH. (b) PC12 cells were
treated with 1 lM AMPH or 250 nM TPA for 5 min per day for 5 days.
After 10 drug-free days, neurite outgrowth was measured. Both
repeated AMPH and repeated TPA elicited an increase in neurite
outgrowth. Values represent means ± SEM. n ‡ 3. ANOVA, p < 0.03. In
post hoc Tukey analysis, *p < 0.05 vs. control.
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AMPH-stimulated DA release (fold stimulation by 3 lM
AMPH after repeated forskolin ¼ 1.84 ± 0.12, n ¼ 6, not
different from vehicle).
Acute treatment with AMPH increased the activation of
PKC and MAP kinase but not PKA in PC12 cells
Our results have demonstrated that PKC inhibitors block and
a PKC activator mimics the AMPH-mediated induction of
neurite outgrowth and enhancement in transporter-mediated
DA release. These results imply that an acute AMPH
treatment could increase PKC activity in the PC12 cells. We
investigated this possibility in two ways: (i) by determining
whether AMPH would elicit the translocation of PKC
activity from the cytosol to the membrane, and (ii) by
examining whether AMPH would increase the phosphoryla-
tion of a protein at a specific PKC substrate site. As shown in
Fig. 6(a), acute treatment with AMPH at a concentration and
time commensurate to those used in the induction experi-
ments (3 lM AMPH for 5 min) decreased the activity of
PKC in the cytosol and increased the activity of PKC in the
membrane as compared to vehicle-treated cells. The reduc-
tion in cytosol PKC activity and increase in membrane-
bound activity of PKC demonstrates translocation and
activation of the enzyme (Nishizuka 1988). Since growth
associated protein-43 (GAP-43) is specifically phosphoryl-
ated by PKC, we used an antibody specific for phosphoser-
ine41-GAP-43 to determine whether AMPH can induce the
phosphorylation of GAP-43. Acute treatment with 3 lM
AMPH for 5 min showed an increase in the phosphorylation
of GAP-43 at serine41 as compared to vehicle control. TPA
(250 nM), used as a positive control, also showed the increase
in the phosphorylation of GAP-43 (Fig. 6b). The amount of
total GAP-43 was not changed by the AMPH or TPA. The
blot in Fig. 6(b) is representative of four experiments which
Fig. 3 Effect of PKC inhibitors and TPA on the induction of enhanced
AMPH-stimulated DA release. (a) PC12 cells were treated for 5 min a
day for 5 days with 1 lM AMPH or vehicle preceded by a 30-min pre-
treatment with (a) 100 nM or 300 nM chelerythrine (CH). The legend
indicates the pre-treatment + the inducing treatment (vehicle or
AMPH, 30 min later). After 10 drug-free days, PC12 cells were har-
vested and perfused as described in Methods and Materials. All
samples received a bolus of 1 lM AMPH for 2.5 min at fraction 4. Due
to the length of tubing and rate of perfusion, the DA elutes at fraction 7.
Results are given in pmol DA/mg protein ± SEM. n ‡ 3. For fraction 7,
ANOVA p £ 0.003. In post hoc Tukey analysis *p < 0.01 vs. A + CH100
and A + CH300 (AMPH and chelerythrine 100 or 300 nM treatment).
(b) PC12 cells were treated with vehicle or 300 nM Ro31-8220 followed
30 min later by 5 min of 1 lM AMPH (AMPH, x-axis) or vehicle (con-
trol, x-axis) for 5 days (pre-treatments are given in the legend in the
Figure). Following 10 drug-free days, AMPH-mediated DA release was
measured in the perfusion as described in part (a) and Materials and
Methods. Results are expressed as the fold stimulation of the DA in
fraction #7 over baseline. *p < 0.05 compared to control-vehicle,
#p < 0.05 compared to AMPH-vehicle, by two-tailed Student’s t-test.
(c) PC12 cells were treated for 5 min a day for 5 days with vehicle
(control), 1 lM AMPH or 250 nM TPA, given 10 drug-free days, har-
vested and perfused as described in Methods and Materials. Results
are given in fold-stimulation of the DA in fraction #7 over baseline.
AMPH and TPA significantly differed from vehicle at *p < 0.05 or
**p < 0.001, respectively, by two-tailed Student’s t-test.
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were quantified by densitometry. The results were calculated
as a ratio of the optical density (O.D.) for the phosphoser41-
GAP-43 band/O.D. for the total GAP-43. The ratio was
0.04 ± 0.009 for the vehicle treatment and 0.52 ± 0.1 for the
AMPH treatment (p < 0.005, n ¼ 4).
Similarly, the ability of the MEK inhibitor, PD98059, to
inhibit the ability of AMPH to induce the enhancement in
DA release suggests that acute AMPH would also increase
MAP kinase activity. As shown in Fig. 7(a), acute treatment
with 3 lM AMPH for 5 min increased the phosphorylation of
MAP kinase with respect to vehicle. NGF (50 ng/mL), used
as a positive control, also showed an increase in the
phosphorylation of MAP kinase. The total amount of MAP
kinase was not altered by the AMPH or NGF treatments.
In contrast, when PC12 cells were treated with 3 lM or
even 10 lM AMPH for 5 min, no significant difference in the
activation of PKA among the treatment groups was detected
(Fig. 7b).
Discussion
We have investigated the role of protein kinases in the
mechanism of induction of two known neuroadaptations
following repeated, intermittent AMPH: neurite outgrowth
and enhanced AMPH-stimulated DA release. Although these
two neuroadaptations are known to occur in brain and PC12
cells following repeated, intermittent AMPH, our study is the
first to demonstrate that induction of these two neuroadap-
tations result from divergent downstream signaling path-
ways. PKC is clearly important in the induction of both
neuroadaptations. This conclusion is based on the fact that
two structurally dissimilar PKC inhibitors, chelerythrine and
Ro31-8220, blocked the induction of both neuroadaptations
and that direct activation of PKC by TPA induced both
neuroadaptions. The demonstration of activation of PKC in
response to AMPH further confirms that AMPH elicits a
rapid activation of PKC that initiates induction of these
events. MAP kinase similarly plays a critical role in the
induction of both neurite outgrowth and the enhancement in
AMPH-mediated DA release. This was confirmed by the fact
that the MEK inhibitor, PD98059, blocked the induction of
both neuroadaptations. In addition, acute AMPH increased
the phosphorylation of MAP kinase. On the contrary, PKA
appears to be required only for the induction of the enhanced
AMPH-stimulated DA release, suggesting that PKA activa-
tion is an event downstream of PKC activation. This
conclusion is further supported by the fact that a short
treatment of the cells with AMPH did not activate PKA and
that direct activation of PKA did not mimic AMPH-induced
neurite outgrowth and DA release.
A role for PKC in the induction of the neuroadaptations in
response to repeated, intermittent AMPH might be expected
based on previous studies demonstrating the requirement of
PKCactivity forAMPH-induced reverse transport (Giambalvo
1992a; Kantor and Gnegy 1998b). Inhibitors of PKC
block AMPH-stimulated DA release whereas PKC activators
increase DA release through the plasmalemmal transporter in
both rat brain and PC12 cells (Kantor and Gnegy 1998b;
Kantor et al. 2001). Similarly, PKC inhibitors block the
expression of the enhanced AMPH-stimulated DA release in
rat striatum following repeated AMPH (Kantor et al. 1999).
Although a role for PKC in the induction of behavioral
sensitization following repeated AMPH has not been
examined, increases in PKC activity have been related
to psychostimulant action. Locomotion stimulated by
intra-accumbens AMPH in the rat was inhibited by prior
intra-accumbal injection of Ro31-8220 (Browman et al.
1998). Both acute AMPH and repeated AMPH increase the
phosphorylation of neuromodulin (GAP-43, F1) in rat striatum
in vivo and rat striatal synaptosomes in vitro at serine-41, the
PKC-substrate site (Gnegy et al. 1993; Iwata et al. 1996,
1997a,b). Kramer et al. (1998) demonstrated that 3,4-methy-
lenedioxymethamphetamine, acting through the serotonin
Fig. 4 Effect of the MEK inhibitor, PD98059 (30 lM), on the ability of
repeated, intermittent AMPH to induce (a) neurite outgrowth and
(b) enhanced AMPH-stimulated DA release. PC12 cells were treated
for 5 min a day for 5 days with 1 lM AMPH (x-axis) or vehicle (control,
x-axis) following a 30-min pre-treatment with 30 lM PD98059 or
vehicle (legend in Figure). After 10 days of withdrawal (a) neurite
outgrowth and (b) DA release in response to 1 lM AMPH were
measured as described in Material and Methods. In (b), results are
given in fold-stimulation of DA in fraction #7 over baseline. Values
represent means ± SEM. n ‡ 3. (a) ANOVA, p < 0.0001. In post hoc
Tukey–Kramer analysis, *p < 0.001 AMPH vs. control-vehicle or
AMPH-PD98059. (b) ANOVA, p < 0.0001. In post hoc Tukey–Kramer
analysis, *p < 0.001 for vehicle-control vs. vehicle-AMPH; **p < 0.001
for PD98059-AMPH vs. vehicle-AMPH.
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transporter in cerebral cortical synaptosomes, leads to an
activation of PKCwithin the nerve terminal. Finally, increased
protein kinase C activity in the VTA may be important in the
development of cocaine-induced sensitization (Steketee 1997).
It is not clear, however, how AMPH or AMPH derivatives
such as 3,4-methylenedioxymethamphetamine activate PKC.
It is unlikely that released DA or norepinephrine is activating
PKC through a DA receptor, since neither D1 receptor nor
D2 receptor antagonists block the induction of these
neuroadaptations by repeated AMPH in PC12 cells (Park
et al. 2002). PC12 cells do not contain a1-adrenergic or
a2-adrenergic receptors (Williams et al. 1998; Molderings
et al. 2002). AMPH is a ligand of a recently identified trace
amine receptor, but that receptor is coupled to an inhibition
of adenylyl cyclase through a Go/Gi mechanism (Bunzow
et al. 2001). r2 receptor ligands are reported to enhance
AMPH-stimulated DA release via activation of PKC activity
(Derbez et al. 2002). AMPH, however, appears not to be
activating the r2 receptor itself since a r2-specific antagonist
had no effect on AMPH-mediated DA release in the
absence of a r2 receptor agonist (Derbez et al. 2002). Since
phosphatase enzymes such as PP2A have been demonstra-
ted to be associated with monoamine transporters in the
membrane, it is possible that protein kinases could
be similarly associated with the transporter (Ramamoorthy
et al. 1998; Bauman et al. 2000). Either binding of
AMPH or the conformational change associated with
inward transport could activate an associated kinase or
recruit a nearby kinase, perhaps by an effect on membrane
lipids or production of arachidonic acid. Arachidonic acid
alters transporter function and can increase PKC activity
(Ingram and Amara 2000). There are reports that AMPH
may increase the concentration of intracellular Ca2+ (Chen
et al. 1998; Kantor et al. 2001; Derbez et al. 2002), which
could elicit PKC translocation and activation as shown in
1321 N1 astrocytoma cells (Trilivas and Brown 1989). We
have evidence that AMPH can increase intracellular Ca2+ in
PC12 cells (Kantor and Gnegy, preliminary results).
Further, we have demonstrated that intracellular Ca2+ is
required for AMPH-mediated outward transport of DA in
both brain and PC12 cells (Kantor and Gnegy 1998a;
Kantor et al. 2001).
Fig. 5 Effect of PKA on AMPH-induced neurite outgrowth (a, b) or
enhanced AMPH-induced DA release (c) in PC12 cells. (a) PC12 cells
were treated with 1 lM AMPH (x-axis) or vehicle (control, x-axis) for
5 min per day for 5 days. Before each vehicle or AMPH treatment, PC
12 cells were pre-treated with vehicle, 30 lM or 100 lM Rp-8-Br-
cAMPS (1 h) or 500 nM H-89 (30 min) (legend in Figure) as described
in Materials and Methods. Neurite outgrowth was measured after 10
drug-free days. Values represent means ± SEM. n ‡ 3. ANOVA
p < 0.0001. In post hoc Tukey–Kramer analysis, *p < 0.001 vs. all
controls and H-89-AMPH. (b) Effect of forskolin on AMPH-induced
neurite outgrowth in PC12 cells. PC12 cells were treated with 10 lM
forskolin for 5 min a day for 5 days as described in Materials and
Methods. Values represent means ± SEM. n ‡ 3. ANOVA p £ 0.004. In
post hoc Tukey–Kramer analysis, *p £ 0.01 vs. vehicle, forskolin.
(c) Effect of H-89 and Rp-8-Br-cAMPS on the induction of enhanced
AMPH-stimulated DA release by repeated, intermittent AMPH. PC12
cells were treated for 5 min a day for 5 days with 1 lM AMPH (x-axis)
or vehicle (control, x-axis) with or without pre-treatment with vehicle,
30 lM or 100 lM Rp-8-Br-cAMPS (1 h) or 500 nM H-89 (30 min). After
10 drug-free days, PC12 cells were harvested and perfused and DA
release was measured as described in Methods & Materials. Results
are given in fold-stimulation of DA in fraction #7 over baseline ± SEM.
n ‡ 3. ANOVA, p < 0.0001. In post hoc Tukey–Kramer analysis,
*p < 0.001 vs. vehicle-control, #p < 0.001 vs. vehicle-AMPH.
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MAP kinase plays an important role in the induction of
neurite outgrowth in PC12 cells (Vaudry et al. 2002). As
expected, the pre-treatment of PC12 cells with the MEK
inhibitor PD98059 blocked the induction of AMPH-induced
neurite outgrowth and it additionally blocked the ability of
AMPH to induce enhanced AMPH-mediated DA release.
PD98059 did not, however, block acute AMPH-stimulated
DA release (data not shown). This result is consistent with
the finding that intra-VTA injection of PD98059 did not
influence the acute behavioral response to cocaine but it
blocked the development of sensitization (Pierce et al. 1999).
MAP kinase has been demonstrated to play a pronounced
role in cocaine-induced behavioral sensitization (Pierce et al.
1999; Valjent et al. 2000) but its role in the induction of
behavioral sensitization and neuroadaptations resulting from
repeated AMPH has not been explored. AMPH increases
extracellular signal-regulated kinase phosphorylation in rat
striatum through activation of metabotropic glutamate recep-
tors (Choe et al. 2002). Activation of D1 receptors, D2
receptors, group I mGluRs and group II mGluRs have all
been demonstrated to lead to MAP kinase phosphorylation
and activation in brain and cultured cells (Otani et al. 1999;
Yan et al. 1999; Narkar et al. 2001; Oak et al. 2001).
However, we found that the D2 dopamine receptor antagon-
ist, sulpiride, and the D1 dopamine receptor antagonist,
SCH23390, did not block AMPH-mediated neurite
outgrowth (Park et al. 2002) or enhanced DA release
(Kantor and Gnegy, preliminary results). Another possibility
is that AMPH can activate PKC followed by MAP kinase
activation. There is evidence that PKC can regulate MAP
kinase by activating Raf-1 (Kolch et al. 1993). We are
presently characterizing the amphetamine-mediated phos-
phorylation of MAP kinase in PC12 cells.
In contrast to the ability of PKC and MAP kinase
inhibitors to block both neuroadaptations, PKA inhibition
blocked the induction of enhanced AMPH-stimulated DA
release in PC12 cells but not the AMPH-mediated induction
of neurite outgrowth. This differentiates the mechanisms by
which AMPH induces neurite outgrowth and enhances DA
release. The role of PKA in the induction of enhanced
AMPH-stimulated DA release is confirmed by the use of two
different PKA inhibitors: H-89, a competitive inhibitor at the
ATP substrate site, and Rp-8-Br-cAMPS (Gjertsen et al.
1995), which binds to the regulatory site of PKA and
blocks enzyme activation. Unexpectedly, H89 but not
Fig. 6 Effect of acute AMPH treatment on PKC activity. (a) PKC
activity measured in cytosol and membrane after acute AMPH treat-
ment in PC12 cells. PC12 cells were incubated for 5 min with or
without 3 lM AMPH. Cytosolic and membrane extracts were prepared
and PKC activity was determined as described in Methods and
Materials. Results are presented as percentage control (vehi-
cle) ± SEM. Control PKC values in the cytosol and membranes were
584 ± 86 pmol/(min mg protein) and 281 ± 56 pmol/(min mg protein),
respectively, n ¼ 6. *p < 0.01 as compared to control (100%) by two-
tailed Student’s t-test. (b) Effect of acute AMPH and TPA on the
phosphorylation of GAP-43. PC 12 cells were treated with 3 lM AMPH
or 250 nM TPA for 5 min. Western blot analysis was performed as
described in Materials and Methods using anti-phosphoser41-GAP-43
(top). The blot was stripped and reprobed for total GAP-43 (bottom).
Fig. 7 Effect of acute AMPH on MAP kinase activity (a) or PKA
activity (b). (a) PC12 cells were treated with 3 lM AMPH for 5 min and
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis as described in Material and Methods. Western blot analysis was
performed to detect phosphorylated MAP kinase (top, two forms:
phospho-p44 and phospho-p42). The blot was subsequently stripped
and reprobed with an antibody measuring total MAP kinase (bottom,
p44 and p42). Cells in lanes 1 and 5 received 5 min of vehicle, lanes 2,
3, 6 and 7 received 3 lM AMPH and lanes 4 and 8 received 50 ng/mL
of nerve growth factor as a positive control. (b) PC12 cells were pre-
pared and incubated for 5 min with or without 3 lM AMPH. Whole cell
lysates were prepared and PKA activity was determined as described
in Materials and Methods. Results represent the ratio of the activity
without cAMP (– cAMP) over that with cAMP (+ cAMP) ± SEM. The
activity of PKA in the control samples is 844 ± 65 pmols/min/mg/
protein. n ¼ 3.
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Rp-8-Br-cAMPS blocked AMPH-induced neurite outgrowth.
Rp-8-Br-cAMPS blocked the induction of the enhanced
AMPH-stimulated DA release, even at the lower dose of
30 lM, demonstrating that it was active at both the 30 lM
and 100 lM concentrations. An action of H-89 other than
PKA inhibition could be responsible for the blockade of
AMPH-induced neurite outgrowth. H-89 has been shown to
inhibit mitogen- and stress-activated protein kinase 1 and
S6-activated protein kinase 1 with a potency similar to or
greater than that for PKA (Davies et al. 2000). Therefore
AMPH-mediated neurite outgrowth may be dependent on
PKC and a MAP kinase pathway and independent of PKA.
PACAP38-induced neurite outgrowth in PC12 cells, for
example, is dependent on PKC and MAP kinase but not on
PKA (Lazarovici et al. 1998), despite the fact that PACAP38
activates adenylyl cyclase activity and increases the forma-
tion of cAMP.
cAMP and PKA activation appear to have some role in the
induction of behavioral sensitization to AMPH but manip-
ulations of this system neither totally mimic nor block the
full range of responses obtained with repeated systemic
AMPH. Repeated intra-VTA injections of cholera toxin,
which activates adenylyl cyclase, has been reported to induce
a short-lasting behavioral sensitization by itself but there was
no enhancement of accumbal AMPH-mediated DA release
(Tolliver et al. 1996). The PKA activator Sp-cAMPS could
not elicit sensitization (Tolliver et al. 1999). These results
would correlate with the inability of forskolin, which
increases cAMP production and PKA activation, to induce
either neuroadaptation in the present study. Conversely,
inhibition of PKA by direct intra-VTA injection of either an
adenylyl cyclase inhibitor or Rp-cAMPS blocked the sensi-
tization induced by repeated intra-VTA AMPH but not
systemic AMPH (Tolliver et al. 1999). AMPH-induced
locomotor sensitization is not seen in RII beta PKA knockout
mice but it is difficult to know whether this is due to a
problem with induction or expression (Brandon et al. 1998).
Therefore, our results in the PC 12 cell correspond with the
results found in rats, that PKA activation is necessary but not
sufficient in the induction of select behaviors and neuroad-
aptations resulting from repeated AMPH.
We were unable to detect a direct effect of AMPH on PKA
activity. Since AMPH can release DA within 3 min, an
AMPH-mediated release of DA or other activity that would
increase cAMP should have been apparent in our 5 min
incubation of the cells with AMPH. This suggests that the
activation of PKA is a later effect of AMPH action. In
addition, as stated above, pre-treatment of the cells with DA
D1 or D2 antagonists before each AMPH treatment did not
block the induction of the neuroadaptations (Park et al.
2002). The more rapid activation of PKC could lead to
downstream activation of the PKA system. For instance,
PKC activation could alter cAMP phosphodiesterase activity,
as shown in PC18 and vascular smooth muscle cells
(Yingling et al. 1994; Liu et al. 2000), or could lead to
increased cAMP biosynthesis (Yingling et al. 1994; Mons
et al. 1998).
In summary, induction of neurite outgrowth and DA
release after repeated, intermittent AMPH treatment is
dependent on PKC and MAP kinase activation in PC12
cells. The cAMP-dependent signaling pathway also contri-
butes to AMPH-induced enhanced DA release in PC12 cells,
suggesting that enhanced neurite outgrowth and DA release
have different mechanisms of induction by repeated AMPH.
Understanding the regulation of the neurite outgrowth and
DA release in PC12 cells after repeated, intermittent
treatment with AMPH will give greater insights into the
neuronal adaptations following withdrawal from repeated
AMPH. They could also contribute to the therapeutics of
neurodegenerative disease. Repeated, intermittent AMPH has
proven useful in ameliorating effects of cerebral ischemia in
rats (Stroemer et al. 1998) and in treatment of stroke in
humans (Crisostomo et al. 1988).
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